Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Calgary
$105,000.00
A gut antigen specific therapeutic nanomedicine for the treatment of inflammatory bowel disease
EF 2013-14
Résumé
Blunting complex immune responses like those leading to inflammatory bowel disease (IBD) without compromising the ability of our immune system to protect us against infections and cancer is a long-sought after, but daunting goal.
The current proposal is founded on the discovery of a new paradigm in the treatment of autoimmune diseases (caused by the white blood cells of the immune system). Traditionally, vaccines have been used to expand white blood cells capable of affording protection against viruses, bacteria or cancer, or to delete white blood cells capable of causing autoimmune diseases. We have developed a vaccine that can cure at least two different autoimmune diseases (type 1 diabetes and multiple sclerosis) by selectively expanding what we call disease-specific autoregulatory white blood cells. These autoregulatory white blood cells then put the brakes on the disease-causing autoimmune attack by suppressing and killing another type of white blood cell of the immune system that is responsible for orchestrating immune responses, including disease-causing ones (the so-called antigen-presenting cells). Since the autoregulatory white blood cells expanded by the nanovaccine selectively target the antigen-presenting cells orchestrating a specific disease, rather than all antigen-presenting cells of the body, they cannot cause generalized suppression of the immune system.
Human IBD is the result of a dysregulated immune response to gut bacteria. We have discovered that regulatory white blood cells targeting a protein expressed by gut bacteria can reset this balance and protect mice from experimental colitis. Here I will test the hypothesis that expansion of gut bacteria-specific autoregulatory white blood cells in vivo by treatment of mice affected with IBD with IBD-specific nanovaccines will blunt the progression of disease.
If this hypothesis is true, this work will pave the way for development of therapeutic nanovaccines for the treatment of human IBD.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
314342
Name
Nanjundappa Roopa
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
A gut antigen specific therapeutic nanomedicine for the treatment of inflammatory bowel disease
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Bacteroides Integrase; Gut Microbiota; Inflammatory Bowel Disease; Nanomedicine; Regulatory T Cells
Abstract
Blunting complex immune responses like those leading to inflammatory bowel disease (IBD) without compromising the ability of our immune system to protect us against infections and cancer is a long-sought after, but daunting goal.
The current proposal is founded on the discovery of a new paradigm in the treatment of autoimmune diseases (caused by the white blood cells of the immune system). Traditionally, vaccines have been used to expand white blood cells capable of affording protection against viruses, bacteria or cancer, or to delete white blood cells capable of causing autoimmune diseases. We have developed a vaccine that can cure at least two different autoimmune diseases (type 1 diabetes and multiple sclerosis) by selectively expanding what we call disease-specific autoregulatory white blood cells. These autoregulatory white blood cells then put the brakes on the disease-causing autoimmune attack by suppressing and killing another type of white blood cell of the immune system that is responsible for orchestrating immune responses, including disease-causing ones (the so-called antigen-presenting cells). Since the autoregulatory white blood cells expanded by the nanovaccine selectively target the antigen-presenting cells orchestrating a specific disease, rather than all antigen-presenting cells of the body, they cannot cause generalized suppression of the immune system.
Human IBD is the result of a dysregulated immune response to gut bacteria. We have discovered that regulatory white blood cells targeting a protein expressed by gut bacteria can reset this balance and protect mice from experimental colitis. Here I will test the hypothesis that expansion of gut bacteria-specific autoregulatory white blood cells in vivo by treatment of mice affected with IBD with IBD-specific nanovaccines will blunt the progression of disease.
If this hypothesis is true, this work will pave the way for development of therapeutic nanovaccines for the treatment of human IBD.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nanjundappa, Roopa
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~